A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Urothelial Carcinoma, Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Subject must weigh at least 35 kg. 2) For Dose Escalation only: Subjects with an advanced solid tumor who are considered refractory to or intolerant of all existing therapy(ies) known to provide a clinical benefit for their condition (i.e., subjects who have progressed on standard therapies known to provide clinical benefit). 3) For Dose Expansion only: All subjects with breast adenocarcinoma that is estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative ("triple negative breast cancer," TNBC) must provide consent to pretreatment and on-treatment fresh tumor biopsies in order to be enrolled.

You may not be eligible for this study if the following are true:

  • 1) History of inflammatory bowel disease, pneumonitis, myocarditis, Stevens-Johnson syndrome or toxic epidermal necrolysis. 2) Known uncontrolled metastases to the central nervous system.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.